Spyglass Pharma, Inc. · NASDAQ:SGP
Spyglass Pharma — Interventional Glaucoma Consortium (IGC) Meeting 2025
14 slides from Spyglass Pharma's conference presentation, Nov 8, 2025
Slide 1: Bimatoprost Drug Pad-IOL System Clinical Update
Bimatoprost Drug Pad-IOL System Clinical Update Dr. Malik Y. Kahook November 8, 2025 (IGC, Salt Lake City)
Slide 2: Outline
Outline: • Bimatoprost Drug Pad-IOL System (BIM-IOL System) Overview • 24-month First-in-Human (FIH) Study Data • 36-month FIH Study Data • 3-month Phase 1/2 Study Data • Summary ©2025 SPYGLASS PHARMA, INC. All rights reserved. 2
Slide 3: The BIM-IOL System aims to deliver a first-in-class solution
The BIM-IOL System aims to deliver a first-in-class solution that addresses both cataracts and elevated IOP in a single, streamlined intervention ©2025 SPYGLASS PHARMA, INC. All rights reserved. 3
Slide 4: 4
4
Slide 5: FIH Feasibility Trial Design
FIH Feasibility Trial Design Single center prospective trial to evaluate the safety and efficacy of the BIM-IOL System in patients previously diagnosed with OAG or OHT and a concomitant cataract and who were taking between one and three topical IOP-lowering medications STUDY M ETHOD BIM-IOL SYSTEM 2
Slide 6: 100% of patients off drops at 24 months
100% of patients off drops at 24 months FIH FEASIB IL ITY T R IAL R ESULT S – IOP LOWERING Mean IOP Reduction Sustained over 24 Months Across All Doses 2 4 M O N T H S P O S T- O P All patients off topical IOP-lowering therapy 42% mean IOP reduction across all three doses 100% of patients with BCDVA
Slide 7: 95% of patients off drops at 36 months
95% of patients off drops at 36 months FIH FEASIB IL ITY T R IAL R ESULT S – IOP LOWERING Mean IOP Reduction Sustained over 36 Months Across All Doses N=21* 3 6 M O N T H S P O S T- O P 95% of patients off topical IOP-lowering therapy 37% mean IOP reduction across all three doses 100% of patients wi
Slide 8: Phase 1/2 Trial Design
Phase 1/2 Trial Design Prospective, multicenter, randomized, double-masked, controlled Phase 1/2 clinical trial to evaluate the safety and efficacy of the BIM-IOL System in patients with OAG or OHT, compared to a control group receiving a commercially available IOL followed by daily administration o
Slide 9: Sustained IOP Reduction at 3 Months
Sustained IOP Reduction at 3 Months PH ASE 1 /2 T R IAL EFFICACY R ESULT S – IOP LOWERING ( I N T E R I M A N A L Y S I S ) M E A N I OP B Y VI SI T – 8 A.M . M E AN I OP B Y VI SI T – 1 0 A .M . ~37% Mean IOP reduction observed across both BIM-IOL System doses at 3 months ©2025 SPYGLASS PHARMA, INC
Slide 10: Drops Eliminated for 97% of BIM-IOL Patients
Drops Eliminated for 97% of BIM-IOL Patients PH ASE 1 /2 T R IAL EFFICACY R ESULT S – IOP M ED ICATIONS ( I N T E R I M A N A L Y S I S ) Proportion of eyes not requiring additional topical IOP-lowering medications * 97% Patients who received the BIM-IOL completely drop-free at 3 months *All Control
Slide 11: Comparable Visual Performance to Industry Standard Monofocal IOL
Comparable Visual Performance to Industry Standard Monofocal IOL PH ASE 1/2 TRIAL EFFICACY RESULTS – VISUAL ACUITY ( I N T E R I M A N A L Y S I S ) 20/20 All arms mean BCDVA of 85-86 letters (~20/20) 100% All patients BCDVA 20/40 or better ©2025 SPYGLASS PHARMA, INC. All rights reserved. 11
Slide 12: Safety Assessment at 3 Months (Interim Analysis)
Safety Assessment at 3 Months (Interim Analysis) • Overall safety results were comparable to routine cataract surgery. • Adverse event (AEs) rates were similar across the 78 mcg (35.3%), the 39 mcg (39.1%) and the control (33.3%) groups. • No serious ocular AEs were observed. ©2025 SPYGLASS PHARMA,
Slide 13: Summary
SUMMARY SpyGlass BIM-IOL System is tackling the patient adherence burden of glaucoma drops at the point of cataract surgery with a single, streamlined intervention 36-month FIH data demonstrates sustained IOP reduction (37%), eliminates need for drops (95%), and improves vision (100% ≥ 20/40)
Slide 14: Questions?
QUESTIONS? Ss SPYGLASS PHARMA ~
Spyglass Pharma — Interventional Glaucoma Consortium (IGC) Meeting 2025 on 6ix